Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians Review Abstract Purpose: This review assesses whether CD3-engaging bispecific antibody therapy can be delivered safely in outpatient oncology settings, with emphasis on cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infection prevention,
Tag: multiple myeloma
CAR T Cell Therapy: The Truth About Off-the-Shelf Treatments in 2026
CAR T Cell Therapy The Truth About Off-the-Shelf Treatments in 2026 Review Key Takeaways Chimeric antigen receptor T cell therapy has transformed the treatment landscape for several hematologic malignancies, offering the potential for durable remission in patients with otherwise refractory disease. Conventional CAR T cell therapy relies on
Monoclonal Antibodies in Relapsed Multiple Myeloma: The Era of Bispecifics and Beyond
Monoclonal Antibodies in Relapsed Multiple Myeloma: The Era of Bispecifics and Beyond Check back later for a possible video summary. Videos are created for most articles. Abstract This paper provides an in-depth review of monoclonal antibody (mAb) therapies in the treatment of relapsed multiple myeloma (MM), with a particular focus on bispecific antibodies
